Supplementary Figure S1 F-I from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure S1. F, Confocal microscopy of SHEP Tet21N cells using anti-PA2G4 (red) and anti-MYCN (green) antibodies. G, Immunoblot analysis of cytoplasmic and nuclear fractions from BE(2)-C and Kelly human neuroblastoma cell lines with antibodies recognizing PA2G4 and MYCN, or GAPDH and topoisomerase as loading controls. H, Confocal microscopy of neuroblastoma (BE(2)-C and Kelly) cells using anti-PA2G4 (red) and anti-MYCN (green) antibodies. Alexafluor 555 anti-rabbit (to detect PA2G4) and Alexafluor 488 anti-mouse (to detect MYCN) were used as the secondary antibodies. I, Real-time PCR mRNA expression of MYCN and PA2G4 in ganglia from homozygote TH-MYCN+/+ mice, compared to wild type littermate control mice, obtained at different postnatal age (weeks).
Authors: Jessica Koach, Jessica K. Holien, Hassina Massudi, Daniel R. Carter, Olivia C. Ciampa, Mika Herath, Taylor Lim, Janith A. Seneviratne, Giorgio Milazzo, Jayne E. Murray, Joshua A. McCarroll, Bing Liu, Chelsea Mayoh, Bryce Keenan, Brendan W. Stevenson, Michael A. Gorman, Jessica L. Bell, Larissa Doughty, Stefan Hüttelmaier, Andre Oberthuer, Matthias Fischer, Andrew J. Gifford, Tao Liu, Xiaoling Zhang, Shizhen Zhu, W. Clay Gustafson, Michelle Haber, Murray D. Norris, Jamie I. Fletcher, Giovanni Perini, Michael W. Parker, Belamy B. Cheung, Glenn M. Marshall
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362372243